On March 24, 2021 Oasmia Pharmaceutical AB, an innovation-focused specialty pharmaceutical company reported that it has been notified by the European Patent Office ("EPO") of its intention to grant a European patent in relation to Oasmia’s XMeNa patent (Press release, Oasmia, MAR 24, 2021, View Source [SID1234577060]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The XMeNa patent protects an improved method for the manufacturing process for Oasmia’s nanotechnology platform XR-17, a unique drug delivery system for selected active pharmaceutical ingredients. The patent adds to Oasmia’s IP portfolio as it extends the market exclusivity for the XR‑17 technology and Oasmia’s lead product Apealea (paclitaxel micellar) into the 2030’s. Apealea is currently being commercialized in key markets around the world.
Commenting on EPO’s announcement, François Martelet, M.D., Chief Executive Officer of Oasmia, said: "This patent is very important for Oasmia as it secures continued protection for our XR-17 platform via its production method until 2036. The patent also provides continued protection for our lead product Apealea plus Docetaxel Micellar, Paccal Vet and Doxophos Vet , which all use the XR-17 platform. It will also allow us apply the XR-17 platform to other internal or acquired projects and to attain further patent protection from the XMeNa patent for such candidates."
In addition to the European patent to be granted by EPO, the corresponding XMeNa patent is already approved in several major pharmaceutical markets, such as the US, India and Australia.
Oasmia recently announced that it signed an agreement with Kazia Therapeutics, an Australian oncology-focused biotechnology company, to acquire exclusive global development rights for Cantrixil, a product candidate in development intended for the treatment of ovarian cancer. In addition to its promise as stand-alone therapy, Cantrixil has the potential to complement Oasmia’s lead product for ovarian cancer, Apealea, through treatment protocols to be developed. It may also offer synergies with Oasmia’s XR-17 technology platform, which could enhance solubility in various routes of administration.